OakChart

ABVC BioPharma Inc

ABVCHealthcare·Biotechnology·USA·Nano·NASD·Nov 12 • 3:59 PM ET

0.96-0.03 (-2.82%)
2026-11-13 12:58 CET
Market cap
$25.99M
Revenue, TTM
0.00 USD m
Net income, TTM
-3.91 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-0.16
Price / earnings
-
Compare

Price

ABVC against its 20, 50 and 200-day averages
Terms2050200
Patternshover a marker to name it
RS 111.001.502.00260K521KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ABVCclose 0.9620-day 1.0050-day 1.02200-day 1.210.9652w low 0.7152-week range, not 6 months

68.5% under the 52-week high of 3.06 on 17 Nov 2025. 52-week low 0.71 on 26 Aug 2026. Last 15 sessions, 25.0% high to low

Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average

Setup. RS line 11
CANSLIM 1 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%; Average Volume: Over 200K — not on the tape: EPS Growth This Year: High (>25%)
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 0 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 1 of 4 — fails: Return on Equity: Over +15% — not on the tape: EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%)
Quality 0 of 5 — fails: Return on Equity: Over +15%; Debt/Equity: Low (<0.1); Current Ratio: Over 1 — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 1 of 4 — fails: Return on Equity: Over +15%; Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Average Volume: Over 500K; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 0 of 4 — fails: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 0 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200; Average Volume: Over 500K

Profile

ABVC
52-week range, 11% of the way up
0.713.06

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.

Employees19
IPONov 10, 2004
Beta0.50
ATR, 14d0.07
Rel volume0.00
Short float2.73%
Insider own18.09%
Inst own4.50%

Snapshot

6 groups

Valuation

Index-
Market Cap$25.99M
Enterprise Value28.60M
Income-3.91M
Sales0.00M
Book / share0.49
Cash / share0.00
Dividend Est.-
Dividend TTM-
Dividend Ex-DateSep 16, 2013
Dividend Gr. 3/5Y- -
Payout-
Employees19
IPONov 10, 2004

Ratios

Price / earnings-
Forward price / earnings-
Price / earnings / growth-
Price / sales-
Price / book1.98
Price / cash371.29
Price / free cash flow-
Value / cash profit-
Value / sales-
Quick Ratio0.20
Current Ratio0.20
Debt / equity0.31
Long-term debt / equity0.10
Options and shortYes / No

Earnings

Earnings / share-0.16
Earnings next year-
Earnings next quarter-
Earnings this year-
Earnings next year-
Earnings growth, 5 years-
Past earnings growth57.67% 39.78%
Past sales growth- -
Earnings vs last year39.04%
Sales vs last year-100.00%
Earnings vs last quarter149.09%
Sales vs last quarter-
Earnings-
Surprise- -

Ownership

Insiders own18.09%
Insider trades0.00%
Institutions own4.50%
Institution trades5.94%
Return on assets-18.86%
Return on equity-31.18%
Return on capital-27.20%
Gross Margin-
Operating margin-
Profit Margin-
20-day average-3.38%
50-day average-5.61%
200-day average-20.26%

Technical

Shares out26.84M
Shares floating22.10M
Short / float2.73%
Short ratio6.93
Short interest0.60M
52-week high3.06 -68.5%
52-week low0.71 +36.4%
Volatility9.87% 6.82%
Average range0.07
Strength index44.65
Market sensitivity0.50
Relative volume0.00
Avg Volume87.05K
Volume0

Performance

Perf Week-0.78%
Perf Month-5.53%
Perf Quarter7.08%
Perf Half Y-10.78%
Perf YTD-54.76%
Perf Year-67.77%
Perf 3Y-9.09%
Perf 5Y-97.10%
Perf 10Y-99.73%
Recommendation-
Target Price-
Prev Close0.96
Price0.96
Change %0.00%

Peers

Mkt cap
TickerCompanyMkt cap
CINGCingulate Inc65.29M
NRXPNRX Pharmaceuticals Inc99.51M
RGCRegencell Bioscience Holdings Ltd2.55B
RLMDRelmada Therapeutics Inc443.75M
TNXPTonix Pharmaceuticals Holding Corp62.96M
KPRXKiora Pharmaceuticals Inc5.88M
CRDFCardiff Oncology Inc56.60M
MIRAMira Pharmaceuticals Inc27.24M
OKYOOKYO Pharma Limited73.47M
SILOSILO Pharma Inc3.03M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 696.31B
VXFVanguard Extended Market Index ETFAUM: 30.79B

News

latest 14 of 200

Quarterly earnings

2023Q3 EPS -0.820, from -1.100 a year earlier. 2024Q3 sales 0.39, from 0.02 a year earlier
EPS
0.0000-2.0502021Q2 EPS -0.800 against -0.40021Q22021Q3 EPS -0.700 against -0.40021Q32021Q4 EPS -0.400 against -0.40021Q42022Q1 EPS -2.05022Q12022Q2 EPS -0.600 against -1.25022Q22022Q3 EPS -1.100 against -2.00022Q32022Q4 EPS -1.500 against -1.50022Q42023Q3 EPS -0.82023Q3
Sales, USD millions
0.5902021Q4 sales 0.20 against 0.2021Q42022Q1 sales 0.0322Q12022Q2 sales 0.31 against 0.0322Q22022Q3 sales 0.04 against 0.0322Q32022Q4 sales 0.59 against 0.0322Q42023Q3 sales 0.0223Q32024Q2 sales 0.1224Q22024Q3 sales 0.3924Q3

The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.

PeriodReportedEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mSurpriseYear-ago quarterAnalystsNext session
2025Q2ended 2025-06-302025-08-14 08:30---0.130--EPS - · sales -vs 2024Q2, year-ago quarter · EPS - · sales --Open +1.01% vs SPY -0.33%. Close +2.36% vs SPY +0.01%
2025Q1ended 2025-03-312025-05-01 08:30---0.056--EPS - · sales ---Open -2.83% vs SPY +1.05%. Close -2.83% vs SPY +0.71%
2024Q3ended 2024-09-302024-11-14 08:30---0.0150.39-EPS - · sales -vs 2023Q3, year-ago quarter · EPS - · sales +2348.3%-Open +0.93% vs SPY +0.02%. Close +2.99% vs SPY -0.64%
2024Q2ended 2024-06-302024-08-15 08:30---0.0890.12-EPS - · sales ---Open +2.68% vs SPY +1.06%. Close -5.19% vs SPY +1.71%
2023Q3ended 2023-09-302023-11-15 08:30-0.820--0.02-EPS - · sales -vs 2022Q3, year-ago quarter · EPS -25.5% · sales -62.4%-Open -5.36% vs SPY +0.31%. Close +11.61% vs SPY +0.21%
2022Q4ended 2022-12-312023-03-31 16:30-1.500-1.500-1.4930.590.03EPS 0.0% · sales +2134.1%vs 2021Q4, year-ago quarter · EPS +275.0% · sales +202.0%2 EPS · 1 salesOpen 0.00% vs SPY -0.13%. Close +0.33% vs SPY +0.38%
2022Q3ended 2022-09-302022-11-14 16:30-1.100-2.000-1.1370.040.03EPS -45.0% · sales +61.5%vs 2021Q3, year-ago quarter · EPS +57.1% · sales -57.3%1Open +6.60% vs SPY +1.53%. Close -4.48% vs SPY +0.85%
2022Q2ended 2022-06-302022-08-15 16:30-0.600-1.250-0.5940.310.03EPS -52.0% · sales +1108.1%vs 2021Q2, year-ago quarter · EPS -25.0% · sales +896.5%2 EPS · 1 salesOpen +4.99% vs SPY -0.26%. Close +7.11% vs SPY +0.20%
2022Q1ended 2022-03-312022-05-16 16:30-2.050--2.0200.03-EPS - · sales -vs 2021Q1, year-ago quarter · EPS +310.0% · sales -90.2%-Open +3.30% vs SPY +1.61%. Close -1.42% vs SPY +2.06%
2021Q4ended 2021-12-312022-03-31 16:30-0.400-0.400-0.200.20EPS 0.0% · sales 0.0%vs 2020Q4, year-ago quarter · EPS -83.3% · sales +214.0%1Open -1.47% vs SPY +0.37%. Close -0.73% vs SPY +0.28%
2021Q3ended 2021-09-302021-11-16-0.700-0.400-0.6720.100.14EPS +75.0% · sales -31.4%vs 2020Q3, year-ago quarter · EPS -22.2% · sales -14.4%1Open -3.93% vs SPY -0.06%. Close -3.93% vs SPY +0.40%
2021Q2ended 2021-06-302021-08-12 08:30-0.800-0.400-0.8070.030.11EPS +100.0% · sales -72.3%-1Open -24.30% vs SPY -0.04%. Close -24.30% vs SPY +0.30%
2021Q1ended 2021-03-312021-06-08-0.500--0.4620.26-EPS - · sales ----
2020Q4ended 2020-12-312021-03-16-2.400-1.000-2.0080.060.12EPS +140.0% · sales -46.4%---
2020Q3ended 2020-09-302021-01-21-0.900--0.9470.12-EPS - · sales ----

Annual earnings

2023FY EPS -2.430, from -5.200 a year earlier. Sales 0.15, from 0.97 a year earlier
EPS
0.0000-5.2002020FY EPS -5.000 against -3.40020202021FY EPS -5.100 against -2.30020212022FY EPS -5.20020222023FY EPS -2.4302023
Sales, USD millions
0.9702020FY sales 0.48 against 0.5420202021FY sales 0.36 against 0.5920212022FY sales 0.9720222023FY sales 0.152023

Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.

earnings feed, not the snapshot. Not the statement ratio.

PeriodEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mP/E, earnings feed
2023FY-2.430--0.15--
2022FY-5.200--5.1870.97--
2021FY-5.100-2.300-5.1250.360.59-
2020FY-5.000-3.400-4.9660.480.54-

Quarterly results

2026Q3 revenue 0.00, from 0.00 a year earlier. 2024Q3 operating margin 12.8%
Revenue, USD millions
0.890-0.892024Q4 revenue 0.0024Q42025Q1 revenue 0.0025Q12025Q2 revenue 0.0025Q22025Q3 revenue 0.0025Q32025Q4 revenue 0.0025Q42026Q1 revenue 0.0026Q12026Q2 revenue 0.0026Q22026Q3 revenue 0.0026Q3
Operating margin
12.80-816.672024Q2 operating margin -816.67%24Q22024Q3 operating margin 12.8%24Q3

From the quarterly statement. Not an estimate.

Estimate revisions

Latest snapshot of each period and type.

No estimate revisions.

Estimate history

Annual
Metric201720182019202020212022202320242025TTMMRQ
EPS per share-3.58-4.804-2.081-4.966-5.125-5.187-1.796-0.42-0.393-0.1569-
Sales USD millions0010010100-
Shares million shares11223381425-27
Quarterly
MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
EPS per share-0.0150.017-0.056-0.13-0.088-0.11-0.061-0.0280.043
Sales USD millions000000000
Shares million shares131415202425262627

Income statement, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/2018
Total Revenue0.000.00-100.0%0.51+240.0%0.15-84.5%0.97+169.4%0.36-25.0%0.48-31.4%0.70+6900.0%0.01
Cost of Goods Sold Incl. D&A0.480.50+150.0%0.20-70.6%0.68+119.4%0.31+1450.0%0.02-66.7%0.06-25.0%0.08-65.2%0.23
Gross Profit-0.48-0.50-261.3%0.31-0.53-180.3%0.66+94.1%0.34-20.9%0.43-31.7%0.63-0.22
Selling, General and Administrative Excl. Other5.316.65+32.7%5.01-19.7%6.24-60.4%15.77+31.0%12.04+34.8%8.93+118.3%4.09+59.8%2.56
Research and Development0.100.12-33.3%0.18-83.0%1.06-60.6%2.69+169.0%1.00+81.8%0.55-47.6%1.05+6.1%0.99
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-5.79-7.15-4.71-6.77-15.11-11.71-8.51-3.46-2.78
Interest Expense0.170.42-49.4%0.83-36.6%1.31+351.7%0.29+26.1%0.23-43.9%0.41-14.6%0.48+4.3%0.46
Unusual Expense0.800.800.000.00-100.0%0.110.00-100.0%0.960.00-100.0%2.61
Net Income Before Taxes-6.91-8.35-5.37-8.02-15.51-11.21-10.81-4.01-6.43
Income Taxes0.000.02-0.11-142.3%0.26-67.5%0.80-3.6%0.83-0.22-0.08-0.37
Consolidated Net Income-6.91-8.38-5.26-8.28-16.31-12.04-10.59-3.93-6.06
Net Income From Continuing Operations-3.91-7.91-4.90-7.79-16.42-12.84-9.79-3.64-5.58
Net Income-3.91-7.91-4.90-7.79-16.42-12.84-9.79-3.64-5.58
EPS (Recurring) per share-0.13-0.37-0.42-1.80-5.16-5.12-4.62-2.08-3.23
EPS (Basic, Before Extraordinaries) per share-0.16-0.39-0.42-1.80-5.19-5.12-4.97-2.08-4.80
EPS (Diluted) per share-0.16-0.39-0.42-1.80-5.19-5.12-4.97-2.08-4.80
EBITDA-5.31-6.65-4.50-6.39-15.09-11.69-8.47-3.40-2.74
Non-Operating Income (Expense)-0.140.02-87.5%0.16+166.7%0.060.00-100.0%0.72-0.94-0.07-0.57
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.983.27+49.3%2.19+1360.0%0.15-97.3%5.56+4.7%5.31+350.0%1.18+5800.0%0.020.0%0.02
Price To Sales Ratio ratio--13.5232.9920.41238.71208.16108.9760,070.78
Gross Margin %--60.42-347.7068.0195.2088.4489.28-3,190.54
Operating Margin %---923.34-4,439.24-1,558.54-3,290.07-1,760.87-492.90-40,031.10
Net Margin %---962.12-5,109.26-1,693.50-3,608.47-2,026.97-518.98-80,152.08
Shares Outstanding million shares26.8425.05+80.6%13.87+74.7%7.94+141.3%3.29+14.6%2.87+19.1%2.41+25.5%1.92+65.5%1.16
Market Capitalization25.9925.99+236.2%7.73-14.8%9.07-55.6%20.41-78.6%95.59-23.1%124.29+46.7%84.70-80.4%431.84

Income statement, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Total Revenue0.000.000.000.000.00-100.0%0.00-100.0%0.000.00
Cost of Goods Sold Incl. D&A0.09-10.0%0.09+12.5%0.09-18.2%0.21+16.7%0.10+900.0%0.08+700.0%0.110.18+20.0%
Gross Profit-0.09-0.09-0.09-0.21-0.10-126.3%-0.08-180.0%-0.11-0.18
Selling, General and Administrative Excl. Other1.15-38.5%0.69-68.8%1.48+155.2%1.98+1137.5%1.87+466.7%2.21+104.6%0.58-83.1%0.16-91.2%
Research and Development0.02-33.3%0.02-33.3%0.030.0%0.030.0%0.03-25.0%0.03-25.0%0.03-57.1%0.03-57.1%
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.24-0.78-1.57-2.20-1.96-4020.0%-2.29-0.69-0.33
Interest Expense0.04+33.3%0.04-69.2%0.05-77.3%0.030.03-86.4%0.13-50.0%0.22-67.6%-
Unusual Expense0.000.000.000.800.000.000.000.00
Net Income Before Taxes-1.39-0.81-1.69-3.02-2423.1%-2.08-2.31-0.940.13
Income Taxes0.000.00-100.0%0.000.000.000.020.000.00-100.0%
Consolidated Net Income-1.39-0.81-1.69-3.02-2423.1%-2.08-2.33-0.940.13
Net Income From Continuing Operations1.15-0.74-1.56-2.77-1304.3%-2.04-2.26-0.840.23
Net Income1.15-0.74-1.56-2.77-1304.3%-2.04-2.26-0.840.23
EPS (Recurring) per share0.04-0.03-0.06-0.09-550.0%-0.09-0.13-0.060.02
EPS (Basic, Before Extraordinaries) per share0.04-0.03-0.06-0.11-650.0%-0.09-0.13-0.060.02
EPS (Diluted) per share0.04-0.03-0.06-0.11-650.0%-0.09-0.13-0.060.02
EBITDA-1.15-0.69-1.48-1.98-1.87-3216.7%-2.21-0.58-0.15
Non-Operating Income (Expense)-0.110.01-91.7%-0.070.02-95.7%-0.09-325.0%0.12-0.03-120.0%0.46
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.85-5.6%0.25-79.8%0.79+1480.0%1.100.901.24+275.8%0.05-98.0%-
Price To Sales Ratio ratio----35,961.3698.8831.2116.06
Gross Margin %--------9,020.85
Operating Margin %--------16,996.85
Net Margin %-------11,663.48
Shares Outstanding million shares26.84+11.0%25.77+32.0%25.77+67.6%25.05+80.6%24.19+90.3%19.53+62.1%15.38+43.7%13.87+74.7%
Market Capitalization25.99-64.0%41.46+8.7%24.91+79.5%52.24+575.8%72.23+742.8%38.14+304.9%13.88-0.6%7.73-14.8%

Balance sheet, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/20182017FY12/31/2017
Cash & Short Term Investments1.39+49.5%0.93+16.3%0.80-45.6%1.47-78.0%6.67+33.4%5.00+3025.0%0.16-33.3%0.24+166.7%0.09
Short Term Receivables0.76-34.5%1.16+52.6%0.76-44.5%1.37-19.9%1.71+71.0%1.00+56.3%0.64+540.0%0.10-96.1%2.55
Inventories0.000.000.000.00-100.0%0.030.000.000.000.00
Other Current Assets0.35+250.0%0.100.0%0.10-33.3%0.15-87.6%1.21+611.8%0.17+112.5%0.08-63.6%0.220.00
Total Current Assets2.50+14.7%2.18+31.3%1.66-44.5%2.99-69.0%9.63+56.1%6.17+601.1%0.88+54.4%0.57-78.4%2.64
Net Property, Plant & Equipment14.75+1182.6%1.15-16.7%1.38-20.7%1.74-13.0%2.00-12.7%2.29+118.1%1.05+105.9%0.510.00
Total Investments and Advances1.88-16.8%2.26-10.7%2.53+201.2%0.84-9.7%0.93-21.8%1.19-64.6%3.36-3.7%3.490.00
Long-Term Note Receivable-0.00-100.0%0.11-95.0%2.22-1.8%2.26-28.5%3.16-22.2%4.060.00-
Intangible Assets--0.000.000.000.000.000.000.00
Deferred Tax Assets--0.00-100.0%0.12-87.8%0.98-45.3%1.79+22.6%1.46+8.1%1.35-
Other Assets1.93-1.0%1.95-7.6%2.11-30.4%3.03+1793.8%0.160.0%0.16-11.1%0.18+500.0%0.030.00
Total Assets21.06+179.3%7.54-3.1%7.78-28.8%10.93-31.5%15.96+8.1%14.77+34.4%10.99+85.0%5.94+125.0%2.64
Short Term Debt Incl. Current Port. of LT Debt1.98-33.3%2.97+25.8%2.36-9.9%2.62+10.1%2.38-11.5%2.69-43.2%4.74-51.3%9.74+777.5%1.11
Accounts Payable0.000.000.000.000.00-100.0%0.020.0%0.020.000.00
Income Tax Payable0.010.00-100.0%0.110.00-----
Other Current Liabilities4.17+16.2%3.59-1.1%3.63+24.3%2.92+122.9%1.31-38.5%2.13+3.9%2.05+65.3%1.24-62.3%3.29
Total Current Liabilities6.16-6.1%6.56+7.5%6.10+10.1%5.54+50.1%3.69-23.8%4.84-28.9%6.81-38.0%10.99+149.8%4.40
Long Term Debt1.60+566.7%0.24-41.5%0.41-48.1%0.79-29.5%1.12-72.5%4.08+1600.0%0.24-11.1%0.270.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.00-100.0%0.020.0%0.02+100.0%0.010.0%0.01-50.0%0.020.00-100.0%0.030.00
Total Liabilities7.76+13.8%6.82+4.4%6.53+3.0%6.34+31.3%4.83-46.0%8.94+26.8%7.05-37.5%11.28+156.4%4.40
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity11.11+803.3%1.23-20.6%1.55-65.2%4.45-59.9%11.10+68.2%6.60+68.8%3.91-5.66-1.76
Total Shareholders Equity11.11+803.3%1.23-20.6%1.55-65.2%4.45-59.9%11.10+68.2%6.60+68.8%3.91-5.66-1.76
Accumulated Minority Interest2.19-0.50-0.30-314.3%0.14+366.7%0.03-0.78-2700.0%0.03-90.6%0.320.00
Total Equity13.30+1747.2%0.72-42.4%1.25-72.8%4.59-58.8%11.13+91.2%5.82+47.7%3.94-5.34-1.76
Total Liabilities & Stockholders Equity21.06+179.3%7.54-3.1%7.78-28.8%10.93-31.5%15.96+8.1%14.77+34.4%10.99+85.0%5.94+125.0%2.64
Book Value Per Share per share0.44+388.9%0.09-55.0%0.20-85.3%1.36-64.9%3.87+41.8%2.73+33.8%2.04-4.87-1.48
Tangible Book Value Per Share per share0.44+388.9%0.09-55.0%0.20-85.3%1.36-64.9%3.87+41.8%2.73+33.8%2.04-4.87-1.48
Full-Time Employees people190.0%190.0%19-17.4%23-23.3%30-11.8%34-2.9%35-7.9%38+280.0%10
Price to Book Ratio ratio1.980.910.582.728.6318.8421.65-75.11-309.74
Return on Assets %-55.30-43.61-83.21-122.15-83.58-76.02-65.69-129.91-300.84
Return on Equity %-128.20-97.42-259.29-211.18-145.07-186.30---
Return on Invested Capital %-62.21-335.14-397.03-313.13-105.01-91.68-87.80--
Quick Ratio ratio0.410.330.270.542.601.270.130.050.60
Current Ratio ratio0.410.330.270.542.611.270.130.050.60

Cash flow, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/2018
Net Income-6.91-8.38-5.26-8.28-16.31-12.04-10.59-3.93-6.06
Depreciation0.480.50+150.0%0.20-47.4%0.38+1800.0%0.02+100.0%0.01-75.0%0.04-33.3%0.06+50.0%0.04
Other Funds (Non Cash)4.335.50+50.3%3.66+17.7%3.11-57.9%7.39+41.6%5.22-17.1%6.30+2639.1%0.23-93.3%3.41
Funds from Operations-2.09-2.37-1.40-4.68-8.03-5.98-4.48-3.73-2.98
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.07-0.62-0.41-183.7%0.49+22.5%0.40-1.30-1.56-471.4%0.42-41.7%0.72
Income Taxes Payable-0.010.01-0.11-200.0%0.11-----
Cash from Operating Activities-2.17-2.99-1.81-4.19-7.64-7.28-6.04-3.31-2.25
Capital Expenditures0.00-0.010.00-0.02-0.12-0.020.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-0.670.000.00-0.34-1.60-0.79-626.7%0.15-0.02-0.16
Purchase of Investments-0.670.000.00-0.34-1.60-0.790.00-0.02-0.16
Sale Or Maturity of Investments-0.000.000.000.000.00-100.0%0.150.000.00
Other Uses-0.31-1.410.000.000.000.000.00-0.020.00
Other Sources0.870.200.000.000.000.00-100.0%0.600.000.00
Cash from Investing Activities-0.11-1.210.00-0.36-1.72-0.81-208.0%0.75-0.04-0.16
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.954.30+223.3%1.33-61.6%3.46-5.5%3.66-64.4%10.27+34.8%7.62+605.6%1.080.00
Repurchase of Common Pref Stock0.000.00-0.010.000.000.000.000.000.00
Sale of Common Pref Stock0.954.30+220.9%1.34-61.3%3.46-5.5%3.66-64.4%10.27+34.8%7.62+605.6%1.080.00
Proceedsfrom Stock Options0.853.31+748.7%0.39-88.7%3.46-5.5%3.66-64.4%10.27+34.8%7.62+605.6%1.080.00
Issuance or Reduction of Debt, Net-0.190.34-45.2%0.62+121.4%0.28-52.5%0.59-0.59-124.1%2.45+12.4%2.18-3.1%2.25
Change in Long Term Debt0.000.00-100.0%0.02-98.6%1.460.00-0.18-111.2%1.61+37.6%1.17+53.9%0.76
Issuance of Long Term Debt0.000.00-100.0%0.34-76.7%1.460.00-100.0%0.24-90.8%2.62+116.5%1.21+51.2%0.80
Reduction of Long Term Debt0.000.00-0.330.000.00-0.41-1.01-0.04-0.04
Net Financing Active Other Cash Flow0.610.00-100.0%0.03-78.6%0.140.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities1.374.64+134.3%1.98-48.8%3.87-8.9%4.25-56.1%9.68-3.9%10.07+208.9%3.26+44.9%2.25
Exchange Rate Effect0.060.02-0.020.00-0.07-0.03-150.0%0.06-4E-06-0.00
Net Change in Cash-0.840.46+206.7%0.15-0.67-5.17-431.4%1.56-67.8%4.84-0.08-0.16
Free Cash Flow--2.99-1.81-4.21-7.76-7.30-6.04-3.31-2.25
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.00-100.0%0.12-86.0%0.86+4.9%0.82-0.22-0.08-0.37

Balance sheet, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Cash & Short Term Investments0.07-92.4%0.09-92.1%0.20-75.6%1.39+49.5%0.92+9.5%1.14+39.0%0.82+12.3%0.93+16.3%
Short Term Receivables0.96-50.3%0.17-88.0%0.20-63.0%0.76-34.5%1.93+58.2%1.42+11.8%0.54-40.0%1.16+52.6%
Inventories0.00-100.0%0.00-100.0%0.00-100.0%0.000.010.010.010.00
Other Current Assets0.37-17.8%0.15-21.1%0.25+150.0%0.35+250.0%0.45+400.0%0.19+90.0%0.10-37.5%0.100.0%
Total Current Assets1.40-57.7%0.41-85.2%0.65-55.8%2.50+14.7%3.31+54.0%2.77+26.5%1.47-17.9%2.18+31.3%
Net Property, Plant & Equipment14.48+9.5%14.58+68.2%14.65+68.4%14.75+1182.6%13.22+56.6%8.67+1.5%8.70+0.5%1.15-86.9%
Total Investments and Advances2.48-9.8%2.49-12.3%1.85-33.0%1.88-16.8%2.75+18.0%2.84+19.3%2.76+11.7%2.26-10.7%
Other Assets1.92-0.5%1.92-2.0%2.59+33.5%1.93-1.0%1.93+35.9%1.96+39.0%1.94+37.6%1.95+37.3%
Total Assets20.30-4.3%19.40+19.5%19.73+32.6%21.06+179.3%21.21+46.7%16.24+11.0%14.88+1.3%7.54-49.5%
Short Term Debt Incl. Current Port. of LT Debt2.65+7.7%1.48-30.8%1.22-56.7%1.98-33.3%2.46-5.4%2.14-14.7%2.82+17.5%2.97+45.6%
Accounts Payable0.000.000.000.000.000.000.000.00
Income Tax Payable0.00-100.0%0.00-100.0%0.010.010.010.02-0.00-100.0%
Other Current Liabilities4.55+11.8%4.21-3.7%4.17+6.6%4.17+16.2%4.07+9.7%4.37+8.2%3.91-5.3%3.59-5.0%
Total Current Liabilities7.19+9.9%5.69-12.9%5.39-19.9%6.16-6.1%6.54+3.5%6.53-0.3%6.73+1.5%6.56+10.6%
Long Term Debt1.34+737.5%1.41+683.3%1.51+788.2%1.60+566.7%0.16+14.3%0.18-21.7%0.17-46.9%0.24-41.5%
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.02+100.0%0.03-25.0%0.00-100.0%0.00-100.0%0.01-66.7%0.04+33.3%0.020.0%0.020.0%
Total Liabilities8.55+27.2%7.13+5.6%6.90-0.3%7.76+13.8%6.72+3.7%6.75-0.9%6.92-0.7%6.82+7.2%
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity13.05+8.2%10.29+46.8%10.77+99.4%11.11+803.3%12.06+44.3%7.01-15.4%5.40-32.7%1.23-86.1%
Total Shareholders Equity13.05+8.2%10.29+46.8%10.77+99.4%11.11+803.3%12.06+44.3%7.01-15.4%5.40-32.7%1.23-86.1%
Accumulated Minority Interest-1.31-153.7%1.98-20.2%2.06-19.2%2.192.442.482.55-0.50
Total Equity11.74-19.0%12.27+29.3%12.83+61.2%13.30+1747.2%14.50+81.7%9.49+21.2%7.96+3.2%0.72-91.6%
Total Liabilities & Stockholders Equity20.30-4.3%19.40+19.5%19.73+32.6%21.06+179.3%21.21+46.7%16.24+11.0%14.88+1.3%7.54-49.5%
Book Value Per Share per share0.49-2.0%0.40+11.1%0.42+20.0%0.44+388.9%0.50-24.2%0.36-47.8%0.35-53.3%0.09-91.9%
Tangible Book Value Per Share per share0.49-2.0%0.40+11.1%0.42+20.0%0.44+388.9%0.50-24.2%0.36-47.8%0.35-53.3%0.09-91.9%
Full-Time Employees people---190.0%---190.0%
Price to Book Ratio ratio1.983.812.214.318.556.391.630.91
Return on Assets %-18.86-39.88-49.85-55.30-27.54-19.80-12.26-43.61
Return on Equity %-31.18-82.15-106.65-128.20-48.12-39.93-27.00-97.42
Return on Invested Capital %7.98-6.30-12.70-21.77-16.71-31.39-15.1115.67
Quick Ratio ratio0.200.070.120.410.500.420.220.33
Current Ratio ratio0.200.070.120.410.510.420.220.33

Cash flow, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Net Income-1.39-0.81-1.69-3.02-2423.1%-2.08-2.33-0.940.13
Depreciation0.09-10.0%0.09+12.5%0.09-18.2%0.21+16.7%0.10+900.0%0.08+700.0%0.110.18+1700.0%
Other Funds (Non Cash)0.98-19.7%0.28-83.7%0.82+164.5%2.251.22+320.7%1.72+132.4%0.31-90.4%-0.58-120.3%
Funds from Operations-0.32-0.44-0.78-0.55-0.77-581.3%-0.53-0.52-0.27
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-0.120.20-0.12-0.04-233.3%-0.19-0.37-0.02-112.5%0.03
Income Taxes Payable0.00-0.01-0.010.01-0.02--0.00
Cash from Operating Activities-0.44-0.24-0.89-0.59-0.96-1300.0%-0.89-0.54-0.25
Capital Expenditures0.000.000.00-0.010.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.00-100.0%0.01-0.680.000.67-0.670.000.00-100.0%
Purchase of Investments0.00-100.0%0.01-0.680.000.81-0.810.000.00-100.0%
Sale Or Maturity of Investments0.00--0.00-0.140.140.000.00
Other Uses-0.05-0.15-0.03-0.08-1.320.000.000.00
Other Sources0.02-86.7%0.030.760.060.150.000.000.00
Cash from Investing Activities-0.02-0.100.05-0.03-0.51-0.670.000.00-100.0%
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.000.000.00
Change in Capital Stock0.00-100.0%0.000.42+2.4%0.53+1225.0%3.36+2000.0%0.00-100.0%0.41+5.1%0.04
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00-0.01
Sale of Common Pref Stock0.00-100.0%0.000.42+2.4%0.53+960.0%3.36+2000.0%0.00-100.0%0.41+5.1%0.05
Proceedsfrom Stock Options0.00-100.0%0.000.320.532.78+1637.5%0.00-100.0%0.00-0.16
Issuance or Reduction of Debt, Net-0.05-0.03-0.660.55+103.7%-0.16-0.02-200.0%-0.03-107.3%0.27+200.0%
Change in Long Term Debt0.000.000.000.000.000.000.00-100.0%-0.27-124.3%
Issuance of Long Term Debt0.000.000.000.00-100.0%0.000.000.00-100.0%0.06-45.5%
Reduction of Long Term Debt0.000.000.000.000.000.000.00-0.33-133.0%
Net Financing Active Other Cash Flow0.460.26-86.7%-0.10-300.0%0.00-100.0%-1.991.95+1400.0%0.050.03
Other Financing Activities Uses0.00-100.0%0.10-0.100.000.04-0.040.000.00
Cash from Financing Activities0.41-65.8%0.23-88.1%-0.34-179.1%1.08+217.6%1.201.93+116.9%0.43-46.9%0.34+385.7%
Exchange Rate Effect0.03-40.0%0.010.00-100.0%0.010.0%0.05-0.05-121.7%0.010.01
Net Change in Cash-0.02-0.11-134.4%-1.190.47+422.2%-0.22-833.3%0.32+300.0%-0.100.09
Free Cash Flow-0.44---0.59-0.96-1300.0%-0.89-0.54-0.25

Revenue breakdown

USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.

Product
Name20252025 share
Pharmaceutical Preparations0.30100.0%
Total0.30100.0%
Region
Name20252025 share
United States0.30100.0%
Total0.30100.0%

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.76%0.6M21.9M99.30K
2026-10-152.70%0.6M21.9M108.30K
2026-09-302.24%0.5M21.9M134.95K
2026-09-151.98%0.5M25.5M141.91K
2026-08-312.41%0.5M21.8M137.80K
2026-08-141.97%0.4M21.8M145.02K
2026-07-312.04%0.4M21.6M138.31K
2026-07-152.20%0.5M21.2M137.50K
2026-06-301.73%0.4M21.2M131.36K
2026-06-151.85%0.4M21.2M110.39K
2026-05-291.23%0.3M21.1M102.97K
2026-05-151.29%0.3M21.1M88.94K
2026-04-301.25%0.3M20.6M86.22K
2026-04-151.43%0.3M20.6M83.68K
2026-03-311.18%0.3M22.6M55.98K
2026-03-131.10%0.2M22.6M60.41K
2026-02-271.09%0.2M22.6M62.33K
2026-02-131.10%0.2M22.5M64.23K
2026-01-301.17%0.3M21.5M64.21K
2026-01-151.59%0.3M21.5M66.26K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.004.400.000.0000.000.000.0000.0000.000
call5.000.004.400.000.0000.000.000.0000.0000.000
call7.500.004.400.000.0000.000.000.0000.0000.000
put2.500.004.601.760.0000.000.000.0000.0000.000
put5.001.606.503.910.0000.000.000.0000.0000.000
put7.504.109.000.000.0000.000.000.0000.0000.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-12S-3/ASEC
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-10DNotice of sales of securities on Form D (Regulation D)SEC
2026-11-028-KCurrent report2026-10-30SEC
2026-09-29DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-28SEC
2026-09-11PRER14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-278-KCurrent report2026-08-27SEC
2026-08-25PRER14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-17424B4SEC
2026-08-17424B4SEC
2026-08-17424B4SEC
2026-08-17424B4SEC
2026-08-12PRER14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-K/A2026-08-03SEC
2026-08-048-KCurrent report2026-08-03SEC
2026-07-28PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-28SEC
2026-07-028-KCurrent report2026-07-02SEC
2026-05-1810-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-15NT 10-Q2026-03-31SEC
2026-03-27POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-03-278-KCurrent report2026-03-27SEC
2026-03-05DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-03-26SEC
2026-03-0310-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-0310-Q/A2025-09-30SEC
2026-03-038-KCurrent report2026-03-03SEC
2026-02-05PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-02-05SEC
2026-01-168-K/A2025-04-30SEC
2025-11-14424B4SEC
2025-11-14424B4SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC1.44%
GEODE CAPITAL MANAGEMENT, LLC0.76%
UBS Group AG0.45%
VANGUARD FIDUCIARY TRUST CO0.37%
STATE STREET CORP0.29%
CITADEL ADVISORS LLC0.28%
BlackRock, Inc.0.22%
NORTHERN TRUST CORP0.19%
XTX Topco Ltd0.19%
PANAGORA ASSET MANAGEMENT INC0.12%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.80%
VANGUARD TOTAL STOCK MARKET INDEX FUND0.44%
Fidelity Extended Market Index Fund0.41%
Fidelity Series Total Market Index Fund0.13%
Fidelity Total Market Index Fund0.12%
Fidelity Nasdaq Composite Index Fund0.06%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. ABVC. Cached 15 minutes. Terms

Some panels did not load: ratings, insider.